Michel Fabbro
Overview
Explore the profile of Michel Fabbro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graybill W, Vergote I, Pothuri B, Anttila M, OMalley D, Lorusso D, et al.
J Comp Eff Res
. 2024 Dec;
14(1):e240133.
PMID: 39641537
To understand the impact of the niraparib individualized starting dose (ISD), compared with fixed starting dose (FSD), on the cost of hematologic adverse event (AE) management from a US payer...
2.
Grisham R, Monk B, Van Nieuwenhuysen E, Moore K, Fabbro M, OMalley D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375168
Background: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with...
3.
Gonzalez-Martin A, Rubio M, Heitz F, Christensen R, Colombo N, Van Gorp T, et al.
J Clin Oncol
. 2024 Sep;
42(36):4294-4304.
PMID: 39292975
Purpose: To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer. Methods: The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov...
4.
Kabirian R, Tredan O, Marme F, Paoletti X, Eberst L, Lebreton C, et al.
Future Oncol
. 2024 Aug;
20(35):2699-2708.
PMID: 39155847
Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are...
5.
Moniot A, Schneider C, Chardin L, Yaniz-Galende E, Genestie C, Etiennot M, et al.
Mol Cancer
. 2024 Aug;
23(1):166.
PMID: 39138571
Background: Ovarian cancer (OC) remains one of the most challenging and deadly malignancies facing women today. While PARP inhibitors (PARPis) have transformed the treatment landscape for women with advanced OC,...
6.
Colombo P, Taoum C, Fabbro M, Quesada S, Rouanet P, Ray-Coquard I
Crit Rev Oncol Hematol
. 2024 Aug;
202:104469.
PMID: 39111459
Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA...
7.
Monk B, Romero I, Graybill W, Churruca C, OMalley D, Knudsen A, et al.
Clin Ther
. 2024 Jul;
46(8):612-621.
PMID: 39019698
Purpose: Niraparib is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor approved for the maintenance treatment of advanced ovarian cancer (OC). Niraparib was originally approved in recurrent OC at a fixed starting...
8.
Darlix A, Monnier M, Castan F, Coutant L, Fabbro M, Denis-Chammas E, et al.
Neurooncol Adv
. 2024 Jul;
6(1):vdae084.
PMID: 38946878
Background: The treatment timing and choice after neurosurgical resection in patients with newly diagnosed diffuse low-grade glioma (DLGG) remain controversial. Indeed, the effect of such treatments must be balanced with...
9.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, et al.
Nat Commun
. 2024 Jun;
15(1):4753.
PMID: 38834579
No abstract available.
10.
Yaniz-Galende E, Zeng Q, Bejar-Grau J, Klein C, Blanc-Durand F, Le Formal A, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2790-2800.
PMID: 38669064
Purpose: This study investigates changes in CD8+ cells, CD8+/Foxp3 ratio, HLA I expression, and immune coregulator density at diagnosis and upon neoadjuvant chemotherapy (NACT), correlating changes with clinical outcomes. Experimental...